Jordanian pharmaceutical manufacturers discussed new commercial opportunities with Barbados' prime minister at a meeting reported on 9 November 2026. Industry representatives presented manufacturing and export capabilities, while Prime Minister Mia Amor Mottley described opportunities for investment and regulatory cooperation. The meeting explored a potential route into Caribbean markets; the report did not announce completed medicine approvals or export contracts.1
The discussion comes during Jordan's first year in the Pharmaceutical Inspection Co-operation Scheme, or PIC/S. The Jordan Food and Drug Administration became a participating authority on 1 January 2026, following documentary assessment and an inspection of its regulatory system. This concerns the authority's inspection capabilities, rather than approval of an individual medicine.2
Cooperation addresses manufacturing oversight
PIC/S says its benefits include inspector training, more consistent interpretation of good manufacturing practice and voluntary sharing of inspection reports. Good manufacturing practice concerns the systems used to make medicines reliably. Cooperation can help another authority assess a factory without unnecessarily repeating work already performed by a trusted inspectorate.3
The organisation explicitly says it is not a trade agreement. It describes reduced inspection duplication, lower costs and improved market access as possible indirect benefits for industry. Some authorities outside the scheme accept manufacturing-practice certificates from participating authorities, but membership alone is not a commitment by every foreign market to accept every product.3
Jordan's regulator presents accession as support for exporters. Its Arabic statement links the recognition to:4
تسهيل انسياب وتصدير الأدوية الأردنية
Facilitating the flow and export of Jordanian medicines.4
Director-general Rana Obeidat described the result as evidence of confidence in Jordan's regulatory performance. That is the regulator's assessment of the benefit. The statement does not identify a blanket exemption from overseas product registration, nor does it report a measured reduction in the time needed to secure each foreign approval.4
Export growth still requires products and investment
At a separate workshop on 23 September, an Amman Chamber of Industry representative reported pharmaceutical exports of JD650.2 million in 2025, compared with JD435.7 million in 2020. He identified lengthy registration procedures, research costs and limited innovation finance as continuing obstacles. Those figures predate accession and cannot measure its subsequent effect.5
The workshop discussed faster registration of innovative medicines and closer links between researchers and manufacturers. Those were recommendations and discussion topics, rather than newly enacted procedures. Turning research into a saleable medicine remains a task alongside demonstrating how the factory operates.5
PIC/S itself updated its institutional framework on 2 November, strengthening emphasis on inspection reliance and regulatory cooperation. Its announcement describes a legally non-binding arrangement between members, distinguishing the scheme from a treaty requiring mutual recognition of inspections. That boundary helps explain why cooperation and unrestricted trade are different propositions.2
The next commercial test is whether the Barbados discussions produce the investment partnerships and market-development arrangements that participants said they wanted to pursue.1